Zymeworks Inc.: Zymeworks Outlines Strategic Priorities and Outlook for 2026

Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability o…

Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued ...
The Gazette

Iowa GOP lawmakers signal renewed scrutiny of public universities in 2026 session

With higher education coming under a more permanent and scrutinizing legislative gaze last session with the establishment of ...
The Gazette

Menopause myths

While some women sail through menopause with few bothersome symptoms, many spend years suffering or maybe just not feeling ...

Emerging Growth Research Maintains Buy Rating on First Phosphate Corp. Following Successful C$9.6 Million Financing and CSE25 Index Inclusion

NEW YORK CITY, NEW YORK / ACCESS Newswire / January 7, 2026 / Emerging Growth Research today announced the release of ...

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program ...